Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

ARKG's genomics thesis faces a timing problem, as much of the index consists of companies with no important clinical data readouts until 2028 or later. Clinical trials remain painstakingly long, and AI is moving faster than trial progress can keep up with, raising the question of when the broader biotech theme becomes overextended. x.com 

Genomics and innovation biotech stocks are an unusually asymmetric short: the companies are 50-100% overvalued even on an aggressive DCF and burn cash while rates break out. They are benefiting from quarter-end markups that end tomorrow, the chart is overbought, and they broke out on Moderna news that has nothing to do with them. Some will benefit from AI, but that is largely narrative. x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Biotech is the next AI trade after compute and memory as the market shifts to the application layer, and the ARK Genomic Revolution ETF could top $100. Biotech runs on data, pattern recognition, R&D and precise manufacturing, all things AI excels at, helping firms like Twist, Tempus and CRISPR make drugs faster and reach profit sooner. The Trump administration is also opening the door to innovation and M&A. Winners are hard to pick, so a basket is easiest; expect volatility. x.com  x.com  x.com  … Show more

ARK Genomic Revolution ETF holds several of 2026's top-performing stocks as its biggest positions. The signal to take profits will be when CNBC features Cathie Wood on TV, likely within one to two months, since CNBC tends to ring the bell at the top. x.com 

AI-driven discovery strengthens the biomedicine case: Anthropic says Claude found a previously unknown enzyme system in bacteriophage DNA, beside a repeating array that resembles CRISPR. Per Anthropic, the few known systems with its features can cut, copy and paste DNA, and such programmable systems have historically helped revolutionize medicine, though what this one does is not yet understood. x.com 

10x Genomics is being re-rated as an AI biology and data-layer company, and that re-rating is real. The stock hit a new 52-week high and is still riding its 21-day moving average. x.com 

AI-enabled healthcare and genomics could deliver the next photonics-like returns, as AI transforms the sector and improves success rates just as it did in tech. The market is getting ready to price these names as future winners, and those that succeed will be real winners. Beaten-down stocks such as AbCellera, Tempus AI and Twist Bioscience, plus the ARK Genomic Revolution ETF, are looking at billion-dollar markets. x.com 

Genomics is likely one of the most important long-term investment themes of the next decade, as AI speeds how life's information is read, understood and edited. Picks: Illumina in sequencing; Tempus AI for AI with genomic data; CRISPR Therapeutics and Beam in gene editing; uniQure (high risk, high payoff) and BioMarin (more certain) in gene therapy; Natera and Guardant Health in diagnostics; Twist Bioscience and Thermo Fisher in tools; Vertex and Alnylam in therapeutics. x.com